MUMBAI, India, Sept. 28 -- Intellectual Property India has published a patent application (202511018162 A) filed by Tanveer Ahmad on February 28, 2025, for A Method For Designing And Constructing A Lentiviral Vector Backbone For Enhanced Titer.
Inventors include Mohammad Sufyan Ansari; and Tanveer Ahmad.
The application for the patent was published on September 25, 2026, under issue no. 39/2026.
Abstract: The present invention provides a method for constructing a high-titer lentiviral vector backbone through targeted structural optimizations. The process involves modifying a base plasmid sequence to include a self-inactivating 3' LTR by deleting U3 subdomain nucleotides, which propagates to the 5' LTR during replication. A hybrid constitutive enhancer sequence is integrated to maintain transcriptional drive while preventing replication-competent recombinants. The architecture is streamlined by excising non-essential bacterial sequences, reducing the plasmid size below ~8.5 kilobases to increase the molar packaging ratio. Efficiency is further enhanced by inserting a structured RNA stem-loop motif for Rev-independent nuclear export and replacing the native polyadenylation signal with a composite sequence to stabilize transcripts. The vector supports multiple pseudotyping envelopes (VSV-G, BaEV, BaEV-Rless, RD-114) for generating diverse CAR-expressing effector cells including CAR-T, CAR-NK, gamma delta T cells, and CD34? hematopoietic stem cells. Validation in HEK293T producer cells achieves an infectious titer exceeding 1×108 transducing units per milliliter (TU/mL). These modifications collectively improve viral yield and biosafety, providing a robust platform for gene therapy and stable transgene delivery.
Disclaimer: Curated by HT Syndication.
